Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial

Table 3 Effect of cilostazol vs. placebo on anthropometric and metabolic parameters

	Mean difference	95% CI for the difference	P-value
BMI (kg/m²)	0.29	−0.03 to 0.61	0.08
Waist circumference (cm)	0.88	−0.28 to 2.03	0.13
Systolic blood pressure (mmHg)	0.76	−4.95 to 6.47	0.79
Diastolic blood pressure (mmHg)	3.07	−1.75 to 7.90	0.21
Fasting glucose (mg/dL)	−3.60	−17.04 to 9.84	0.59
HbA1c (%)^*	−0.01	−0.05 to 0.03	0.53
Fasting insulin (μIU/mL)^*	0.07	−0.12 to 0.25	0.45
HOMA-IR^*	0.06	−0.17 to 0.29	0.59
QUICKI	−0.00	−0.01 to 0.01	0.70
Total cholesterol (mg/dL)	−1.21	−11.46 to 9.05	0.81
Triglyceride (mg/dL)^*	0.05	−0.15 to 0.26	0.61
HDL-C (mg/dL)	0.98	−3.54 to 5.51	0.66
LDL-C (mg/dL)	−0.71	−9.65 to 8.24	0.87
hsCRP (mg/L)^*	−0.38	−0.84 to 0.09	0.11
Mean baPWV (cm/sec)	31.42	−55.67 to 118.50	0.47
Adiponectin (ng/mL)^*	−0.07	−0.17 to 0.03	0.16
IL-6 (pg/mL)^*	−0.18	−0.61 to 0.26	0.38
TNF-α (ng/dL)^*	−0.08	−0.22 to 0.06	0.27
MCP-1 (ng/dL)^*	0.08	−0.11 to 0.27	0.41
sVCAM-1 (ng/dL)	105.18	10.65 to 199.71	0.03
sICAM-1 (ng/dL)^*	0.06	−0.05 to 0.18	0.28

HOMA-IR homeostasis model assessment of insulin resistance, QUICKI, quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
Mean difference = placebo-cilostazol.
^*Statistical significance was estimated after logarithmic transformation.

ISSN: 1758-5996